Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used in the treatment of type 2 diabetes mellitus. However, the effects of GLP-1 RAs on glycemic control and body weight vary. In this commentary, the authors explain how this variability may stem from the medications' impact on gastric motility and upper gastrointestinal symptoms. They further underscore the importance of assessing gastric emptying and gastrointestinal symptoms using validated instruments. [ABSTRACT FROM AUTHOR]